Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2022

Trabelsi Grati Olfa, Zemoura Leila, Nhy Caroline, Daniel Catherine, Melaabi Samia, Callens Céline, Gauthier Villars Marion, Bièche Ivan, Girard Nicolas

Abstract excerpt

First-line therapy in advanced non-small-cell-lung-cancer (NSCLC) is based on chemotherapy except for patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab is administrated. However, patients with somatic-EGFR-mutated tumors had usually been excluded from clinical applications of immune checkpoint inhibitors (ICIs). Germline-EGFR-mutated-patients are known...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Germ-Line Mutation

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 36156246
DOI: 10.1016/j.lungcan.2022.09.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.PMID 36156246Read ↗

First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.Semantic proximity Read ↗

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read ↗

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read ↗

A Rare EGFR R748T Mutation in A Squamous Cell Lung Carcinoma Patient with PD-L1 High Expression and Response to Immuno-Chemo Combination TherapySemantic proximity Read ↗

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R.Semantic proximity Read ↗

Complete remission after pembrolizumab monotherapy in a non-small cell lung cancer patient with PD-L1 negative, high tumor mutational burden, and positive tumor-infiltrating lymphocytes: A case report.Semantic proximity Read ↗

Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report.Semantic proximity Read ↗

[Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation].Semantic proximity Read ↗

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read ↗

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutationsSemantic proximity Read ↗

A Case Report of a Long-Surviving Elderly Patient with Lung Squamous Cell Carcinoma and Oncogenic Driver AlterationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.